An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion)


Por: Economopoulou, P, Pouliakis, A, Kyprianou, M, Pantazopoulos, A, Spathis, A, Kotsantis, I, Cavalieri, S, Oliva, M, Rogado, J, Pena, C, Iglesias, L, Baste, N, Castelo, B, Fountzilas, E, Martinez-Vila, C, Salamero, MC, Triaridis, S, Frutos, IDD, Unal, E, Ong, EHW, Chua, MLK, Papouliakos, S, Hamid, H, Saba, NF, Mesia, R, Licitra, L and Psyrri, A

Publicada: 1 abr 2026
Resumen:
Background: We aimed to investigate the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with head and neck cancer (HNC). Methods: The HERODOTUS registry is a multicenter observational study which included patients with any HNC and a COVID-19 diagnosis. Clinical data were extracted from medical records of patients from 3/2019 until 12/ 2022. As the study involved numerous variables that would possibly overlap, a cluster analysis was performed for the prediction of patient death due to COVID-19. Results: Among 403 COVID-19 positive cases, 76 patients died (all-cause fatality rate 18.8%) ;21 deaths were attributed to COVID-19. On multivariate analysis, poor performance status (OR: 8.96, 95% CI: 2.07-47.86), development of sepsis (OR:8.99, 95% CI:1.48-72.4) or ARDS (OR:11.64, 95% CI:2.53--64.42), administration of chemotherapy (OR: 28.08, 95% CI: 5.49-158.92) and hospitalization (OR:7.32, 95% CI: 2.49-23.3) had a negative impact on survival, whereas vaccination was protective (OR: 0.29, 95% CI: 0.11-0.75). The clustering procedure resulted in the automated creation of four clusters and identified the following determinants of death: COPD, autoimmune disease, squamous/adenocarcinoma histology, disease stage, fever, diarrhea, fatigue, first line immunotherapy/immunochemotherapy, second line chemotherapy/cetuximab, cisplatin, chemoradiation, ARDS, coagulopathy, heart failure, treatment modifications due to COVID-19, surgical complications and vaccination. Conclusions: This is the largest cohort of patients with HNC and COVID-19. All-cause fatality rate in patients with HNC and COVID-19 was approximately 19%. Among 41 covariates with discriminatory power analyzed, 20 were identified as major determinants of death. Vaccination was protective against death from COVID-19.

Filiaciones:
Economopoulou, P:
 Attikon Univ Hosp, Dept Internal Med 2, Sect Med Oncol, 1st Rimini St, Haidari 12462, Athens, Greece

Pouliakis, A:
 Attikon Univ Hosp, Dept Internal Med 2, Sect Med Oncol, 1st Rimini St, Haidari 12462, Athens, Greece

Kyprianou, M:
 Attikon Univ Hosp, Dept Internal Med 2, Sect Med Oncol, 1st Rimini St, Haidari 12462, Athens, Greece

Pantazopoulos, A:
 Attikon Univ Hosp, Dept Internal Med 2, Sect Med Oncol, 1st Rimini St, Haidari 12462, Athens, Greece

Spathis, A:
 Attikon Univ Hosp, Dept Internal Med 2, Sect Med Oncol, 1st Rimini St, Haidari 12462, Athens, Greece

Kotsantis, I:
 Attikon Univ Hosp, Dept Internal Med 2, Sect Med Oncol, 1st Rimini St, Haidari 12462, Athens, Greece

Cavalieri, S:
 Fdn IRCCS Ist Nazl Tumori Milano, Head & Neck Med Oncol Dept INT, 1st Giacomo Venezian St, I-20133 Milan, Italy

 Fdn IRCCS Ist Nazl Tumori Milano, Dept Oncol & Hemato Oncol UNIMI, 1st Giacomo Venezian St, I-20133 Milan, Italy

 Univ Milan, 1st Giacomo Venezian St, I-20133 Milan, Italy

Oliva, M:
 Catalan Inst Oncol ICO, Dept Med Oncol, Phase Funct Unit 1, IDIBELL, 199th Granvia Hosp Ave, Lhospitalet De Llobregat 08908, Barcelona, Spain

Rogado, J:
 Hosp Univ Infanta Leonor, Med Oncol Dept, 80th Ave Gran Via Este, Vallecas 28031, Madrid, Spain

Pena, C:
 Fdn Ctr Oncol Galicia, Med Oncol, 1st Doctor Camilo Veiras St, La Coruna 15009, Spain

Iglesias, L:
 Inst Invest Sanitaria Hosp, Internal Med Med Oncol, 12 Octubre,Ave Cordoba S-N, Usera 28041, Madrid, Spain

Baste, N:
 Hosp Clin Barcelona, Med Oncol Dept, IDIBAPS, 170th Villarroel St, Leixample 08036, Barcelona, Spain

Castelo, B:
 Hosp Univ La Paz, Med Oncol, 261st Castellana St, Fuencarral El Pardo 28046, Madrid, Spain

Fountzilas, E:
 St Lukes Clin, Dept Med Oncol, Panorama, Thessaloniki 55236, Greece

Martinez-Vila, C:
 Xarxa Assistencial Univ Althaia Manresa, Med Oncol, Manresa 08243, Barcelona, Spain

:
 ICO Inst Catala Oncol Badalona, Dept Med Oncol, CARE Program, B ARGO Grp,IGTP, 21stA Can Ruti St, Badalona 08916, Barcelona, Spain

Triaridis, S:
 Aristotle Univ Thessaloniki, Head & Neck Med Oncol Dept, Thessaloniki 54124, Greece

 Aristotle Univ Thessaloniki, Dept Oncol & Hemato Oncol UNIMI, Thessaloniki 54124, Greece

Frutos, IDD:
 Hosp Galdakao Usansolo, Oncol, Galdakao 48960, Bizkaia, Spain

Unal, E:
 Istanbul Univ, Cerrahpasa Fac Med, Surg Oncol Dept, Koca Mustafapasa Cd 53, TR-34098 Fatih, Istanbul, Turkiye

Ong, EHW:
 Natl Canc Ctr Singapore, Div Radiat Oncol & Med Sci, 30th Hosp Blvd, Singapore 168583, Singapore

Chua, MLK:
 Natl Canc Ctr Singapore, Div Radiat Oncol & Med Sci, 30th Hosp Blvd, Singapore 168583, Singapore

Papouliakos, S:
 Gennimatas Hosp Athens, Dept ENT, 154th Mesoge Ave, Athens 11527, Greece

Hamid, H:
 Al Moalem Med City, Surg, JH62 FPW, Al Khurtum, Khartoum, Sudan

Saba, NF:
 Emory Univ, Winship Canc Inst, Hematol & Med Oncol Dept, 1365 Clifton Rd NE, Atlanta, GA 30322 USA

:
 ICO Inst Catala Oncol Badalona, Dept Med Oncol, CARE Program, B ARGO Grp,IGTP, 21stA Can Ruti St, Badalona 08916, Barcelona, Spain

Licitra, L:
 Fdn IRCCS Ist Nazl Tumori Milano, Head & Neck Med Oncol Dept INT, 1st Giacomo Venezian St, I-20133 Milan, Italy

 Fdn IRCCS Ist Nazl Tumori Milano, Dept Oncol & Hemato Oncol UNIMI, 1st Giacomo Venezian St, I-20133 Milan, Italy

 Univ Milan, 1st Giacomo Venezian St, I-20133 Milan, Italy

Psyrri, A:
 Attikon Univ Hosp, Dept Internal Med 2, Sect Med Oncol, 1st Rimini St, Haidari 12462, Athens, Greece
ISSN: 13688375





Oral Oncology
Editorial
Elsevier Ltd., RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Reino Unido
Tipo de documento: Article
Volumen: 175 Número:
Páginas:
WOS Id: 001701096500001
ID de PubMed: 41722171

MÉTRICAS